Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/15/2024 | $39.00 → $30.00 | Equal-Weight → Underweight | Morgan Stanley |
| 5/30/2024 | $36.00 | Neutral | Goldman |
| 5/10/2024 | $40.00 | Buy → Hold | TD Cowen |
| 5/30/2023 | $45.00 | Equal-Weight | Morgan Stanley |
| 3/29/2023 | $43.00 | Neutral | UBS |
| 1/6/2023 | $55.00 | Overweight → Equal-Weight | Morgan Stanley |
| 1/5/2023 | Outperform → Mkt Perform | Raymond James | |
| 1/3/2023 | $66.00 → $55.00 | Buy → Neutral | BofA Securities |
Baxter International Inc. (NYSE:BAX), a global medtech leader, will present at the 7th Annual Evercore HealthCONx Conference on Thursday, December 5, 2024. Joel Grade, Baxter's chief financial officer, is scheduled to present at 9:10 a.m. Eastern Time. The live webcast of Baxter's presentation can be accessed at www.baxter.com and will be available for replay through Tuesday, June 3, 2025. About Baxter Every day, millions of patients and caregivers rely on Baxter's leading portfolio of diagnostic, critical care, kidney care, nutrition, hospital and surgical products used across patient homes, hospitals, physician offices and other sites of care. For more than 90 years, we've been oper
Baxter International Inc. (NYSE:BAX), a global medtech leader, will present at the Jefferies London Healthcare Conference on Wednesday, November 20, 2024. Joel Grade, Baxter's chief financial officer, is scheduled to present at 11:00 a.m. Greenwich Mean Time. The live webcast of Baxter's presentation can be accessed at www.baxter.com and will be available for replay through Monday, May 19, 2025. About Baxter Every day, millions of patients and caregivers rely on Baxter's leading portfolio of diagnostic, critical care, kidney care, nutrition, hospital and surgical products used across patient homes, hospitals, physician offices and other sites of care. For more than 90 years, we've bee
Baxter International Inc. (NYSE:BAX), a global medtech leader, will present at the Stifel 2024 Healthcare Conference on Monday, November 18, 2024. Joel Grade, Baxter's chief financial officer, is scheduled to present at 8:35 a.m. Eastern Time. The live webcast of Baxter's presentation can be accessed at www.baxter.com and will be available for replay through Saturday, May 17, 2025. About Baxter Every day, millions of patients and caregivers rely on Baxter's leading portfolio of diagnostic, critical care, kidney care, nutrition, hospital and surgical products used across patient homes, hospitals, physician offices and other sites of care. For more than 90 years, we've been operating at
10-Q - BAXTER INTERNATIONAL INC (0000010456) (Filer)
8-K - BAXTER INTERNATIONAL INC (0000010456) (Filer)
8-K - BAXTER INTERNATIONAL INC (0000010456) (Filer)
Addition of Mr. Craig complements current board expertise with deep financial, broad operational and public company board experience Baxter International Inc. (NYSE:BAX), a global medtech leader, today announced it has appointed Jeffrey (Jay) A. Craig, former executive chair and chief executive officer (CEO) of Meritor Corporation, to its board of directors. Mr. Craig will serve on Baxter's Audit Committee. His appointment is effective today and brings the total number of directors serving the company to 12. "We are excited to welcome Jay to Baxter's board," said José (Joe) E. Almeida, chair, president and CEO. "As a former CEO, CFO, COO and public company auditor, Jay's broad-based busin
Tentarix Biotherapeutics today announced the appointment of Andrew Kidd, MD, as chief executive officer. Mr. Kidd joins Tentarix with a distinguished career of over two decades of executive and biotech experience. He was most recently the president and CEO of Aptinyx (NASDAQ:APTX), a clinical-stage CNS-focused biotech company. His previous experience includes senior leadership roles at Baxter International (NYSE:BAX) and The Boston Consulting Group. "We are excited to welcome Andy to the Tentarix team at this critical inflection point for the company," said Tentarix Chairman Donald Santel. "Under Andy's leadership, we are poised to effectively execute on our existing partnered programs wi
Baxter International Inc. (NYSE:BAX), a global medtech leader, today announced it has appointed Joel Grade as executive vice president and chief financial officer (CFO), reporting to Baxter chairman, president and CEO, José (Joe) E. Almeida, effective Oct. 18, 2023. At that time, Brian Stevens, who has served as the company's interim CFO since May 31, 2023, will transition to his prior role as senior vice president, chief accounting officer and controller. "Joel is a seasoned global financial executive with decades of deep operational and broad business experience as well as a proven record of results-driven impact," said Mr. Almeida. "I am confident we will benefit from Joel's leadership
SC 13G/A - BAXTER INTERNATIONAL INC (0000010456) (Subject)
SC 13G/A - BAXTER INTERNATIONAL INC (0000010456) (Subject)
SC 13G - BAXTER INTERNATIONAL INC (0000010456) (Subject)
4 - BAXTER INTERNATIONAL INC (0000010456) (Issuer)
3 - BAXTER INTERNATIONAL INC (0000010456) (Issuer)
4 - BAXTER INTERNATIONAL INC (0000010456) (Issuer)
Morgan Stanley downgraded Baxter from Equal-Weight to Underweight and set a new price target of $30.00 from $39.00 previously
Goldman initiated coverage of Baxter with a rating of Neutral and set a new price target of $36.00
TD Cowen downgraded Baxter from Buy to Hold and set a new price target of $40.00
For Immediate Release: October 18, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: This week, FDA continues ongoing efforts to increase access and supply of IV and peritoneal dialysis (PD) fluids following Hurricane Helene-related damage to Baxter International Inc.’s facility in Marion, North Carolina. Specifically, FDA acted quickly to c
Ares Management Corp. (NYSE:ARES) and HPS Investment Partners are spearheading a $3 billion credit facility to finance Carlyle Group Inc.’s (NASDAQ:CG) potential acquisition of Baxter International Inc.’s (NYSE:BAX) kidney-care division. This debt package includes a $2.5 billion unitranche loan and a $450 million revolver. Oaktree Capital Management is also involved in the financing, and smaller lenders may participate after signing. Also Read: Medical Devices Giant Baxter Secures FDA Approval For New Infusion Pump System. The financing terms suggest an interest rate five percentage points above the Secured Overnight Financing Rate, placing the division Vantive’s leverage at 4.2
https://www.bloomberg.com/news/articles/2024-07-23/ares-hps-line-up-3-billion-debt-for-carlyle-s-baxter-unit-bid?sref=y3YMCJ4e
- Reuters
Baxter International Inc. (NYSE:BAX), a global medtech leader, today announced that its Board of Directors has declared a quarterly cash dividend of $0.17 per share of common stock. The dividend is payable on Jan. 2, 2025, to stockholders of record as of Nov. 29, 2024. The indicated annual dividend rate is $0.68 per share of common stock. This dividend represents the new quarterly dividend rate for Baxter in anticipation of the divestiture of its Kidney Care business segment to Carlyle (NASDAQ:CG), which is expected to close in late 2024 or early 2025, subject to receipt of customary regulatory approvals and satisfaction of other closing conditions. Over its 93-year history, Baxter has co
Baxter third-quarter 2024 sales totaled $3.85 billion1 Third-quarter total Baxter U.S. GAAP2 diluted earnings per share (EPS) were $0.271; adjusted total Baxter diluted EPS were $0.801, exceeding the company's previously issued guidance Third-quarter sales from continuing operations of $2.70 billion increased 4% on both a reported and constant currency basis3, reflecting growth across all segments4 Third-quarter U.S. GAAP diluted EPS from continuing operations were $0.12; adjusted continuing operations EPS were $0.49 Baxter continues to make significant progress restoring production at its North Cove facility following the unprecedented impact of Hurricane Helene in western North C
Baxter International Inc. (NYSE:BAX), a global medtech leader, will host a conference call to discuss its third-quarter 2024 financial results on Friday, November 8, 2024 at 7:30 a.m. Central Time. To participate in this conference call please follow this link https://events.q4inc.com/attendee/391655054 to pre-register for the call and receive the call information. This call is also being webcast and can be accessed through Baxter's website at www.baxter.com. The conference call will be recorded by Baxter and is copyrighted material. It cannot be recorded or rebroadcast without Baxter's permission. About Baxter Every day, millions of patients and caregivers rely on Baxter's leading portf